A Phase Ⅲ Clinical Study of SYS6010 in Combination With Osimertinib in Patients With Locally Advanced or Metastatic NSCLC

NCT07376382 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

680

Enrollment

INDUSTRY

Sponsor class

Conditions

NSCLC

Interventions

DRUG: SYS6010
DRUG: Osimertinib
DRUG: platinum-pemetrexed

Sponsor

CSPC Megalith Biopharmaceutical Co.,Ltd.